Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals Medical Device PIC

Johnson & Johnson MedTech and CED Medical Sign Third Strategic Cooperation Agreement to Expand Neurointerventional Partnership Behind Qiangyida Stent

Fineline Cube Sep 1, 2026
Company Deals PIC

WestGene and CREATE Sign License Deal to Co‑Develop In Vivo CAR‑T Therapies

Fineline Cube Aug 31, 2026
Company Deals PIC

Simnova Closes nearly RMB 400 Million Series B to Advance CAR‑NK Candidate SNC103

Fineline Cube Aug 31, 2026
Company Deals PIC

Leaderna Therapeutics Closes Series A+ Led by Grand View Capital to Advance Oligonucleotide Pipeline

Fineline Cube Aug 31, 2026
Company Drug PIC

Eli Lilly Wins FDA Approval for Mounjaro Cardiovascular Risk Reduction in Type 2 Diabetes

Fineline Cube Aug 31, 2026
Company Deals Medical Device PIC

Johnson & Johnson MedTech and CED Medical Sign Third Strategic Cooperation Agreement to Expand Neurointerventional Partnership Behind Qiangyida Stent

Fineline Cube Sep 1, 2026
Policy / Regulatory

NMPA CDE Issues Draft Guideline to Reduce or Replace Animal Testing for Monoclonal Antibodies, Opening Public Comment

Fineline Cube Sep 1, 2026
Company Policy / Regulatory

Shanghai RAAS’s SR604 Enters NMPA CDE Rare Disease Encouragement Program for Hemophilia and Factor VII Deficiency Treatment

Fineline Cube Sep 1, 2026
Company Drug

Luye Pharma Launches Rotigotine Luye in UK for Parkinson’s and Restless Leg Syndrome

Fineline Cube Apr 11, 2025

China-based Luye Pharma Group (HKG: 2186) announced the market launch of Rotigotine Luye in the...

Company Deals

Astellas Pharma Partners with Shanghai Pharma on Zolbetuximab Commercialization

Fineline Cube Apr 11, 2025

Japan-based Astellas Pharma Inc. (TYO: 4503) announced a strategic partnership with Shanghai Pharmaceuticals (SPH; SHA:...

Company Drug

CK Life Sciences Reports Promising Preclinical Results for TROP2-Targeted Cancer Vaccine

Fineline Cube Apr 11, 2025

China-based CK Life Sciences (HKG: 0775) has announced positive early results from preclinical studies of...

Company Drug

Kangtai Biological’s Pentavalent Rotavirus Vaccine Enters Phase III Trials

Fineline Cube Apr 10, 2025

Shenzhen Kangtai Biological Products Co., Ltd (SHE: 300601) announced the enrollment of the first patient...

Company Drug

Zelgen Biopharma’s ZG005 Approved for Gastrointestinal Tumor Trials in China

Fineline Cube Apr 10, 2025

Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) announced that it has received approval from China’s...

Company Drug

HemaCell’s XJ-MK-002 Gains FDA Orphan Drug Designation for Giant Platelet Syndrome

Fineline Cube Apr 10, 2025

China-based Suzhou Xueji Biotechnology Co., Ltd (HemaCell), a pioneer in platelet regeneration-focused cell therapy, announced...

Company Drug

IVIEW Therapeutics’ IVIEW-1201 Gains FDA Orphan Drug Designation for Fungal Keratitis

Fineline Cube Apr 10, 2025

China-based IVIEW Therapeutics Inc. announced that it has received Orphan Drug Designation (ODD) from the...

Company Drug

Hansoh Pharma’s Ibrexafungerp Approved for Vulvovaginal Candidiasis in China

Fineline Cube Apr 10, 2025

China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) announced this week that it has received...

Company Drug

Hengrui Pharmaceuticals’ Ivarmacitinib Approved for Atopic Dermatitis

Fineline Cube Apr 10, 2025

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced that it has received additional indication approval...

Company Drug

Beijing StarMab’s SM2275 Receives FDA IND Approval for Dual-Target Cancer Therapy

Fineline Cube Apr 10, 2025

China-based Beijing StarMab BioMed Technology, Ltd. announced that it has received Investigational New Drug (IND)...

Company

GE Healthcare Appoints Jeannette Bankes as President and CEO of Patient Care Solutions

Fineline Cube Apr 10, 2025

GE Healthcare Technologies Inc. (NASDAQ: GEHC) announced this week the appointment of Jeannette Bankes as...

Company Medical Device

Wantai Bio’s Tuberculosis Test Kit Joins UNOPS StopTB Procurement List

Fineline Cube Apr 10, 2025

China-based Beijing Wantai Biological Pharmacy Enterprise Co., Ltd (SHA: 603392) announced that its Tuberculosis infection...

Company Drug

B. Braun’s DUPLEX System Approved by FDA for Piperacillin and Tazobactam

Fineline Cube Apr 10, 2025

B. Braun Medical Inc., a US-based healthcare company, announced that the U.S. Food and Drug...

Company Drug

Sino Biopharma’s TQB3019 Gains NMPA Approval for Hematological Malignancies

Fineline Cube Apr 10, 2025

China-based Sino Biopharmaceutical Ltd (HKG: 1177) announced that it has received clinical approval from the...

Company Medical Device

Peijia Medical’s YonFlow Stent Approved by China’s NMPA

Fineline Cube Apr 10, 2025

Peijia Medical Ltd (HKG: 9996) announced that it has received market approval from China’s National...

Company Medical Device

Gaush Meditech’s Corneal Confocal Microscope Approved in Jiangsu

Fineline Cube Apr 10, 2025

Suzhou-based Gaush Meditech Ltd (HKG: 2407) announced that it has received market approval from the...

Company Drug

Simcere Pharmaceutical Gains NMPA Approval for FGFR2b-Targeted ADC SIM0686

Fineline Cube Apr 10, 2025

China-based Simcere Pharmaceutical Group (HKG: 2096) announced that it has received clearance from the National...

Company Deals

Sinopep-Allsino Partners with Gulf Pharmaceutical for Semaglutide API Supply

Fineline Cube Apr 10, 2025

Jiangsu-based Contract Development and Manufacturing Organization (CDMO) Sinopep-Allsino Biopharmaceutical Co., Ltd (SHA: 688076) has signed...

Policy / Regulatory

U.S. Tariffs on Pharmaceuticals and Their Impact on China’s Medical Industry

Fineline Cube Apr 9, 2025

The U.S. administration’s decision to impose tariffs on pharmaceutical imports, effective April 9, has sent...

Company Drug

Sichuan Biokin Launches Phase III Trial for BL-B01D1 in Urothelial Carcinoma

Fineline Cube Apr 9, 2025

China-based Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506) has announced the first patient enrollment in...

Posts pagination

1 … 228 229 230 … 714

Recent updates

  • NMPA CDE Issues Draft Guideline to Reduce or Replace Animal Testing for Monoclonal Antibodies, Opening Public Comment
  • Shanghai RAAS’s SR604 Enters NMPA CDE Rare Disease Encouragement Program for Hemophilia and Factor VII Deficiency Treatment
  • Eisai Launches LEQEMBI IQLIK Subcutaneous Auto-Injector for Early Alzheimer’s Disease in the United States
  • Trump Signs Nine New MFN Drug Pricing Agreements, Expanding Pharma Deals to 26 Companies Covering 89% of Branded Market
  • Laekna Doses First Patient in Phase I Study of LAE118 PI3Kα Inhibitor for Advanced Solid Tumors, Licensed to Vasque Bio for Up to USD 527 Million
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • PIC
  • Policy / Regulatory
  • R&D

You Missed

Policy / Regulatory

NMPA CDE Issues Draft Guideline to Reduce or Replace Animal Testing for Monoclonal Antibodies, Opening Public Comment

Company Policy / Regulatory

Shanghai RAAS’s SR604 Enters NMPA CDE Rare Disease Encouragement Program for Hemophilia and Factor VII Deficiency Treatment

Company Drug

Eisai Launches LEQEMBI IQLIK Subcutaneous Auto-Injector for Early Alzheimer’s Disease in the United States

Policy / Regulatory

Trump Signs Nine New MFN Drug Pricing Agreements, Expanding Pharma Deals to 26 Companies Covering 89% of Branded Market

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2026 | Fineline Information & Technology | BlogData by Themeansar.